

1 **Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-**
2 **CoV-2**

3
4 Julia R. Port*, Claude Kwe Yinda*, Victoria A. Avanzato, Jonathan E. Schulz, Myndi G.
5 Holbrook, Neeltje van Doremalen, Carl Shaia, Robert J. Fischer, Vincent J. Munster#

6
7

- 8 1. *Laboratory of Virology, Division of Intramural Research, National Institute of*
9 *Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA*
10 2. *Rocky Mountain Veterinary Branch, Division of Intramural Research, National*
11 *Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton,*
12 *MT, USA*

13 * These authors contributed equally

14 # Corresponding author. vincent.munster@nih.gov

15
16

17 **Abstract**

18 Airborne transmission, a term combining both large droplet and aerosol transmission, is
19 thought to be the main transmission route of SARS-CoV-2. Here we investigated the
20 relative efficiency of aerosol transmission of two variants of SARS-CoV-2, B.1.1.7 (alpha)
21 and lineage A, in the Syrian hamster. A novel transmission caging setup was designed
22 and validated, which allowed the assessment of transmission efficiency at various
23 distances. At 2 meters distance, only particles $<5 \mu\text{m}$ traversed between cages. In this
24 setup, aerosol transmission was confirmed in 8 out of 8 ($N = 4$ for each variant) sentinels
25 after 24 hours of exposure as demonstrated by respiratory shedding and seroconversion.
26 Successful transmission occurred even when exposure time was limited to one hour,
27 highlighting the efficiency of this transmission route. Interestingly, the B.1.1.7 variant
28 outcompeted the lineage A variant in an airborne transmission chain after mixed infection
29 of donors. Combined, this data indicates that the infectious dose of B.1.1.7 required for
30 successful transmission may be lower than that of lineage A virus. The experimental proof
31 for true aerosol transmission and the increase in the aerosol transmission potential of
32 B.1.1.7 underscore the continuous need for assessment of novel variants and the
33 development or preemptive transmission mitigation strategies.

34

35

36

37

38

39 **Introduction**

40 More than one year has passed since the declaration of the severe acute respiratory
41 syndrome coronavirus 2 (SARS-CoV-2) pandemic in March 2020 by the World Health
42 Organization (WHO). Epidemiological data suggests that the principal mode of infection
43 with SARS-CoV-2 is via airborne transmission¹⁻⁵. The general definition held by the WHO
44 states that large droplets disperse over a short distance and settle in the upper respiratory
45 tract, while aerosols (<5 μm) can form droplet nuclei, travel over long distance, and
46 significantly deposit in the lower respiratory tract⁶. Both forms are typically considered
47 airborne transmission. For influenza A virus, another respiratory virus, studies have
48 elucidated the airborne potential and discussed the relative contribution of droplets vs.
49 aerosols and the site of viral exposure and shedding⁷⁻¹⁰. Similar data for SARS-CoV-2 is
50 currently unavailable.

51 Genetic variants of SARS-CoV-2 continue to be detected worldwide and variants of
52 concern (VOCs) are defined by phenotypic changes including enhanced transmission
53^{11,12}. Transmissibility is a function of infectiousness, susceptibility, contact patterns
54 between individuals, and environmental stress on the pathogen during transmission¹³. In
55 our previous work, we have demonstrated that aerosol exposure increases severity of
56 disease in the Syrian hamster and that airborne transmission with a lineage A variant over
57 short distances (<10 cm) is very efficient^{14,15}. However, in these studies we could not
58 differentiate between large particles and true aerosols. No study so far has demonstrated
59 the potential of SARS-CoV-2 for true aerosol transmission with particles <5 μm . Here, we
60 specifically designed transmission cages to model aerosol transmission over 2 meters
61 distance, at which only particles <5 μm traverse. We showed highly efficient aerosol

62 transmission of SARS-CoV-2 at 2 meters distance within one hour of exposure. Lastly,
63 we demonstrated increased airborne transmission competitiveness of B.1.1.7 over a
64 lineage A variant.

65

66 **Results**

67 **Design and validation of hamster aerosol transmission cages**

68 Direct contact and airborne transmission have been demonstrated in the Syrian hamster
69 model for SARS-CoV-2 ^{14,16}. However, demonstration of true aerosol transmission of
70 SARS-CoV-2 should only include particles <5 μm , over longer distances and in the
71 absence of any other potential transmission routes such as fomite or direct contact. To
72 determine if SARS-CoV-2 can transmit successfully via aerosols, we designed and
73 validated a caging system to study the relationship between particle size and distance.
74 The design consisted of two rodent cages connected via a polyvinylchloride (PVC)
75 connection tube (76 mm inside diameter) which allowed airflow, but no direct animal
76 contact, from the donor to the sentinel cage. The distance between donor and sentinel
77 cage could be varied (16.5, 106, or 200 cm) by exchanging the PVC connection tube
78 **(Supplemental Figure 1 A, B)**. Directional airflow from the donor to the sentinel cage
79 was generated by negative pressure. The air velocity generated by the airflow through
80 the connection tube averaged at 327, 370, and 420 cm/min for the 16.5, 106, and 200 cm
81 distances, respectively **(Supplementary Table 1)**. This allowed for 30 cage changes per
82 hour.

83 We next validated the caging design using an aerodynamic particle sizer to analyze the
84 aerodynamic size of particles (dynamic range from <0.5-20 μm) traversing from donor to

85 sentinel cage. Droplets and aerosols were generated in the donor cage (20% (v/v)
86 glycerol solution, sprayed with a standard spray bottle) and the particle size profile was
87 determined at the beginning and end of the connecting tube to study the potential for size
88 exclusion of the respective cage setups. The reduction of particles was size and distance
89 dependent. At a distance of 16.5 cm between cages, relatively limited size exclusion of
90 the generated particles was observed; $\geq 6.9\%$ of particles 5-10 μm and $\geq 42.8\%$ of particles
91 $\geq 10 \mu\text{m}$ did not travel into the sentinel cage (**Fig 1 A/D**). At the intermediate distance of
92 106 cm between cages an increased reduction of number of particles and size exclusion
93 was observed; $\geq 70\%$ of particles $\geq 5 \mu\text{m}$ did not traverse into the sentinel cage and no
94 particles $\geq 10 \mu\text{m}$ were detected. Hence, while in the donor cage 4.86% of detected
95 particles were $>5 \mu\text{m}$, in comparison the particle profile in the sentinel cage contained
96 only 2% particles $>5 \mu\text{m}$ (**Fig 1 B/E**). At the longest distance of 200 cm, we observed an
97 almost complete size exclusion of particles $\geq 5 \mu\text{m}$; $\geq 95\%$ of particles 5-10 μm did not
98 traverse and no particle $\geq 10 \mu\text{m}$ were detected in the sentinel cage. The composition
99 profile of particles in the sentinel cage comprised only 0.5% particles $\geq 5 \mu\text{m}$ (**Fig 1 C/F**).
100 These combined results demonstrate that we have developed a novel caging system to
101 effectively investigate the impact of distance and particle size exclusion on the
102 transmission of SARS-CoV-2. The overall absence of particles $\geq 10 \mu\text{m}$ and extensive
103 reduction of particles 5-10 μm indicate that the caging system with the distance of 200
104 cm is suitable to study true aerosol transmission; whereas, the 16.5 and 106 cm set-ups
105 are suitable to study airborne transmission occurring via droplet, aerosols or a
106 combination thereof.

107

108 **SARS-CoV-2 aerosol transmission over 2 meters distance**

109 Experimental SARS-CoV-2 airborne transmission has been demonstrated over short
110 distances in the Syrian hamster model ^{14,15}. Using the validated caging system, we first
111 investigated short-distance airborne transmission. For each distance, four donor animals
112 were inoculated intranasal (I.N) with 8×10^4 TCID₅₀ SARS-CoV-2 lineage A. After 12 hours,
113 the infected animals were placed into the donor (upstream) side of the cages and four
114 sentinels were placed into the downstream cages (2:2 ratio) and were exposed for 72
115 hours.

116 At a distance of 16.5 cm, SARS-CoV-2 successfully transmitted to all the sentinels at 12
117 hours post exposure (HPE) (**Figure 2 A/B**). Genomic (g)RNA and subgenomic (sg)RNA,
118 a marker for replicating virus, were found in oropharyngeal swabs of all sentinels at 48
119 HPE. At a distance of 106 cm, SARS-CoV-2 gRNA and sgRNA were detected in
120 oropharyngeal swabs of one sentinel as early as 12 HPE. At 48 HPE all sentinels were
121 positive for gRNA and sgRNA in oropharyngeal swabs (**Figure 2 C/D**). At a distance of
122 200 cm, no respiratory shedding was detectable in any sentinel 12 HPE, but at 48 HPE
123 all sentinels were positive for gRNA and sgRNA in oropharyngeal swabs (**Figure 2 E/F**).
124 Additionally, at 14 days post exposure (DPE) all sentinels from all three groups had
125 seroconverted, as demonstrated by high antibody titers against SARS-CoV-2, measured
126 by anti-spike ELISA (**Supplemental Table 2**). These data demonstrate the ability of
127 SARS-CoV-2 to transmit over long and short distances and suggest that transmission
128 efficiency may be distance dependent.

129

130 **Increased binding to Syrian hamster ACE2 and increased respiratory shedding of**

131 **B.1.1.7 variant**

132 Epidemiological studies have indicated that the emergence of the B.1.1.7 (alpha variant)
133 was due to increased transmission over preceding virus lineages ¹⁷. To investigate
134 whether the increased transmission potential of B.1.1.7 on the population level is
135 determined by changes in transmission potential at the individual level, we compared the
136 airborne transmission kinetics of the B.1.1.7 with the prototype lineage A virus.

137 First, we assessed the suitability of the Syrian hamster as a model to compare SARS-
138 CoV-2 variant transmission. The B.1.1.7 spike binds with greater affinity to the human
139 ACE2, potentially explaining the increased transmission ¹⁸. Therefore, we compared the
140 *in-silico* binding efficiency of spike receptor binding domain (RBD) of a lineage A and
141 B.1.1.7 variant with human and hamster ACE2. At position 501 of the B.1.1.7 spike RBD,
142 the asparagine residue is substituted by tyrosine, which allows increased interactions with
143 residues on ACE2 through stacking of aromatic sidechains and hydrogen bonding, hence
144 higher affinity binding to human ACE2 ¹⁹. A sequence alignment between human and
145 hamster ACE2 revealed variation at the amino acid level, however only two residues differ
146 within the interface with SARS-CoV-2 RBD. At positions 34 and 82, histidine and
147 methionine are replaced by glutamine and asparagine, respectively, in the hamster ACE2
148 **(Figure 3 A, B)**. These substitutions are not located in the immediate vicinity of the N501Y
149 mutation, suggesting that B.1.1.7 should also exhibit higher affinity binding to hamster
150 ACE2.

151 To confirm that the observed enhanced binding affinity of B.1.1.7 to human ACE2 was
152 also present for hamster ACE2 we directly compared viral entry using a VSV pseudotype

153 entry assay. No significant difference in entry between human and hamster ACE2 with
154 either lineage A or B.1.1.7 was observed. For both human and hamster ACE2, B.1.1.7
155 demonstrated significantly increased entry compared to the lineage A variant (human
156 ACE2 median lineage A/B.1.1.7 = 156.8/256 (relative entry to no spike), $p < 0.0001$ and
157 hamster ACE2 median lineage A/B.1.1.7 = 144.6/197.5 (relative entry to no spike), $p =$
158 0.003, $N = 14$, Mann-Whitney test) (**Figure 3 C**).

159 We next investigated if the enhanced binding affinity of B.1.1.7 to hamster ACE2
160 translated to differences in viral replication and shedding dynamics *in-vivo*. Hamsters (N
161 = 10) were inoculated I.N. with 10^2 TCID₅₀ of SARS-CoV-2 lineage A variant (A) or B.1.1.7.
162 Regardless of variant, weight loss was observed in all animals with a maximum at 7 days
163 post inoculation (DPI), after which animals began to recover (**Figure 3 D**, $N = 5$, median
164 weight loss lineage A/B.1.1.7 = 7.5/8.2%). Five out of ten hamsters per group were
165 euthanized at 5 DPI and lung tissue was harvested to assess viral replication in the lower
166 respiratory tract. Lung tissue of animals inoculated with B.1.1.7 contained higher levels
167 of gRNA and significantly higher levels of sgRNA (**Figure 3 E**, $N = 5$, ordinary two-way
168 ANOVA, followed by Sidak's multiple comparison test, median lineage A/B.1.1.7 =
169 9.9/10.5 log₁₀ copies/g and $p = 0.0614$; median lineage A/B.1.1.7 = 9.2/10 log₁₀ copies/g
170 and $p = 0.0045$, respectively). Infectious virus titers in the lungs were not significantly
171 different between the variants (**Figure 3 F**, $N = 5$ median lineage A/B.1.1.7 = 6.3/6.5 log₁₀
172 TCID₅₀/g). At 14 DPI, all remaining animals had seroconverted. Anti-spike IgG ELISA
173 titers were significantly increased in animals inoculated with B.1.1.7 (**Figure 3 G**, $N = 5$,
174 Mann-Whitney test, median lineage A/B.1.1.7 = 102400/204800 and $p = 0.0394$). Next,
175 we studied differences in shedding from the upper respiratory tract. sgRNA could be

176 detected in two animals at 12 hours after inoculation (HPI) with lineage A variant and in
177 one animal inoculated with B.1.1.7. sgRNA was detected at similar levels for both groups
178 at 24 HPI (**Figure 3 H**). At 3 DPI, a significant increase in sgRNA was seen in B.1.1.7
179 inoculated animals. In both groups sgRNA levels from oropharyngeal swabs started to
180 drop at 5 DPI, levels in the B.1.1.7 animals remained somewhat higher (3 DPI median
181 lineage A/B.1.1.7 = 6.9/7.6 and 5 DPI median lineage A/B.1.1.7 = 6.0/6.5 copies/mL
182 (\log_{10}). This translated to a significant difference when comparing the cumulative
183 shedding until 5 DPI (**Figure 3 I**, area under the curve (AUC), N = 5, Mann-Whitney test,
184 median lineage A/B.1.1.7 = 726/770 cumulative copies/mL (\log_{10}) and p = 0.0079).

185

186 **Efficient aerosol transmission with B.1.1.7**

187 We repeated the aerosol transmission experiment at 106 cm and 200 cm as described
188 above for B.1.1.7. Aerosol transmission of B.1.1.7 was equally as efficient as for lineage
189 A; all sentinels demonstrated respiratory shedding and seroconversion (**Figure 4**
190 **A/B/C/D, Supplementary Table 1**).

191 We next set out to determine the transmission efficiency of both lineage A and B.1.1.7
192 within a limited exposure window of either one or four hours at 200 cm distance. First,
193 four donor animals were I.N. inoculated with 8×10^4 TCID₅₀ SARS-CoV-2 lineage A and
194 four donors with B.1.1.7. Sentinel were exposed in a 2:2 ratio at 12 hours post inoculation
195 for a duration of four hours. Transmission via aerosols occurred even when time of
196 exposure was limited for both variants. Both gRNA and sgRNA shedding were detected
197 24 hours after exposure in oropharyngeal swabs of three out of four sentinel animals

198 exposed to B.1.1.7 and lineage A (**Figure 4 E/F**). At 3 DPE, all sentinels displayed gRNA
199 and sgRNA shedding.

200 Next, the same experiment was repeated with the exposure time limited to one hour.

201 gRNA was detected 24 hours post exposure in oropharyngeal swabs of three out of four

202 sentinels exposed to B.1.1.7 and two out of four sentinels exposed to lineage A,

203 respectively (**Figure 4 G/H**). sgRNA was detected in oropharyngeal swabs of two out of

204 four sentinels exposed to B.1.1.7 and two out of four sentinels for lineage A, respectively.

205 At 3 DPE, whilst all sentinels exposed to B.1.1.7 were positive for gRNA and sgRNA, viral

206 RNA was only detected in two of four sentinels exposed to lineage A. Viral loads in swabs

207 did not differ significantly between the two variants. To ensure the differences observed

208 in transmission were not due to increased donor shedding, we compared viral loads in

209 oropharyngeal swabs taken from donor animals after exposure. B.1.1.7 did not impact

210 the respiratory shedding of the donors at this time point (**Figure 4 I/J**, N = 4, ordinary two-

211 way ANOVA, followed by Sidak's multiple comparison test, four hours: gRNA p = 0.8737,

212 sgRNA p = 0.1049, one hour: gRNA p = 0.6853, sgRNA p = 0.2450). The same

213 experiment was repeated on day three after inoculation of the donors. No transmission

214 occurred at this time point; we did not observe gRNA in oropharyngeal swabs of any

215 sentinel on consecutive days and no sgRNA was detected in any swab taken during three

216 days post exposure (**Supplementary Figure 2**). These data suggest that aerosol

217 transmission for B.1.1.7 may be more efficient compared to lineage A, and is independent

218 of amount of virus shed by donor.

219

220 **B.1.1.7 variant demonstrates increased airborne transmission competitiveness**

221 To assess the transmission efficiency in direct competition between lineage A and B.1.1.7
222 variants, we employed the 16.5 cm cage system to conduct a transmission chain study.
223 Donor animals (N = 8) were inoculated I.N. with 1×10^2 TCID₅₀ SARS-CoV-2 (1:1 lineage
224 A:B.1.1.7 mixture). Dual infection presented with comparable weight loss and shedding
225 profile to inoculation with either variant (**Supplementary Figure 3 A/B**). After 12 hours
226 donors were co-housed with eight sentinels (Sentinels 1) (2:2 ratio) for 24 hours (**Figure**
227 **5 A**). Immediately after, the eight sentinels were co-housed with eight new sentinels
228 (Sentinels 2) (2:2 ratio) for 24 hours and donor animals were relocated to normal rodent
229 caging. This sequence was repeated for Sentinels 3. For each round, the previous
230 sentinels were housed in the upstream cage and became the new donors. We assessed
231 transmission by measuring viral RNA in oropharyngeal swabs taken from all animals at 2
232 DPI/DPE. While all donor animals (median gRNA = 7.3 copies/mL (\log_{10}), median sgRNA
233 = 7.0 copies/mL (\log_{10})) and all Sentinels 1 (median gRNA = 7.0 copies/mL (\log_{10}), median
234 sgRNA = 6.8 copies/mL (\log_{10})) demonstrated robust shedding, viral RNA could only be
235 detected in four out of eight Sentinels 2 (median gRNA = 2.5 copies/mL (\log_{10}), median
236 sgRNA = 1.8 copies/mL (\log_{10})), and in one Sentinels 3 animal (**Figure 5 B/C**). We
237 compared infectious virus titers in the swabs. While all donor animals (median = 4.25
238 TCID₅₀ (\log_{10}) and all Sentinels 1 had high infectious virus titers (median = 4.5 TCID₅₀
239 (\log_{10})), infectious virus could only be detected in four Sentinels 2 (median = 0.9 TCID₅₀
240 (\log_{10})), and no Sentinels 3 animals (**Figure 5 D**). We then proceeded to compare the
241 viral loads in the lungs of these animals at 5 DPE. As expected, viral RNA was only
242 detected in animals that were positive for SARS-CoV-2 in their corresponding
243 oropharyngeal swab. While all donor animals (median sgRNA = 10.0 copies/g (\log_{10})) and

244 all Sentinels 1 had high gRNA levels in the lung (median sgRNA = 10.0 copies/mL (\log_{10}),
245 viral RNA could only be detected in four Sentinels 2 (median sgRNA = 4.3 copies/mL
246 (\log_{10}), and no RNA was detected in any Sentinels 3 (**Figure 5 E**). We compared the
247 gross pathology of these lungs. Lungs from Sentinels 1 demonstrated SARS-CoV-2
248 infection associated pathology as previously described^{14,20,21}. Pathology was only seen
249 in three Sentinels 2 and no Sentinels 3 (**Figure 4 F, Supplementary Table 3,**
250 **Supplementary Figure 3 C**). This suggests that transmission very early after exposure
251 may be restricted and that not all animals were able to efficiently transmit the virus to the
252 next round of naïve sentinels.

253 To determine the competitiveness of the variants we analyzed the relative composition of
254 the two viruses in the swabs using next generation sequencing and compared the
255 percentage of B.1.1.7/lineage A at 2 DPE (**Figure 5 G, Supplementary Table 4**). We
256 observed one donor with increased amounts of lineage A variant (55%), while in the
257 remaining seven animals the B.1.1.7 variant was increased (54-74% range). After the first
258 airborne transmission sequence, two sentinels shed increased amounts of lineage A
259 variant (55% and 84%), while the remaining six shed more B.1.1.7; five of which shed
260 nearly exclusively B.1.1.7 (>96%). After the second round of the airborne transmission
261 sequence, three out of four sentinel animals shed exclusively B.1.1.7 and one animal
262 shed exclusively lineage A. Due to low amounts of viral RNA, two sentinels in the
263 Sentinels 2 and the one sentinel in the Sentinels 3 group could not be successfully
264 sequenced. We analyzed these samples by duplex-qRT-PCR applying a modified $2^{-\Delta\Delta Ct}$
265 method (**Supplementary Table 4**). One animal in the Sentinels 2 group only shed B.1.1.7
266 (no lineage A PCR positivity). The other shed nearly exclusively lineage A (0.0007-fold

267 increase of B.1.1.7), while, interestingly, the transmission event of this animal to the
268 Sentinels 3 animal was exclusively B.1.1.7. Taken together, B.1.1.7 demonstrated
269 increased competitiveness; in 10 out of 13 airborne transmission events B.1.1.7
270 outcompeted lineage A and only in three events infection with lineage A was established
271 as the dominant variant.

272

273 **Discussion**

274 Epidemiological studies in humans strongly suggest that aerosol transmission plays a
275 major role in driving the SARS-CoV-2 pandemic ²²⁻²⁴. Yet formal proof of aerosol
276 transmission of SARS-CoV-2 has not been provided and would rely on demonstration of
277 long distance transmission in the absence of other transmission routes ²⁵. Here we
278 demonstrated efficient transmission of SARS-CoV-2 between Syrian hamsters via
279 particles $<5 \mu\text{m}^6$ over 200 cm distance. Additionally, we present first qualitative analyses
280 of the efficiency of transmission, showing that even within one hour transmission can
281 occur at a distance of 200 cm between Syrian hamsters. Whereas several SARS-CoV-2
282 transmission studies in hamsters and ferrets have been performed, none of these studies
283 were able to differentiate between large and small droplet transmission ^{14,15,26-28}. In our
284 previous work, specifically designed cage dividers were used to generate an airflow
285 system minimizing large droplet cross-over. While the number of large droplets was
286 markedly reduced, aerosol transmission could not be conclusively demonstrated ¹⁴.
287 Within the currently described transmission caging only 2% and 0.5% of particles found
288 in the sentinel side were $\geq 5 \mu\text{m}$ at 106 and 200 cm distance, respectively, strongly
289 suggesting that the transmission observed in these cages is by true aerosols. This is an

290 important finding in two regards. First, epidemiological conclusive evidence for aerosol
291 transmission of SARS-CoV-2 is currently still lacking, because it is difficult to determine
292 with certainty the route or combination of routes of transmission. Second, particles $<5\ \mu\text{m}$
293 are expected to reach the respiratory bronchioles and alveoli. While respirable aerosol
294 ($<2.5\ \mu\text{m}$), thoracic aerosol ($<10\ \mu\text{m}$) and inhalable aerosol in general ²⁹ all may be
295 relevant to infection with SARS-CoV-2 ³⁰, it has been suggested that direct deposition into
296 the lower respiratory tract may decrease the necessary infectious dose ³¹. Indeed, our
297 previous work has demonstrated that aerosol inoculation in the Syrian hamster is highly
298 efficient (25 TCID₅₀, particles $<5\ \mu\text{m}$ ³²) and is linked to increased disease severity due to
299 direct deposition of the virus into the lower respiratory tract ¹⁴.

300 The data presented here need to be considered in the context of inherent differences
301 between the Syrian hamster model and human behavior. Experimentally, animals were
302 exposed to a unidirectional airflow at timepoints chosen for optimal donor shedding, which
303 likely contributed to the high efficiency of aerosol transmission even at 200 cm distance
304 after only one hour of exposure. However, this approximates human exposure settings
305 such as restaurants or office spaces.

306 Increased risk of airborne transmission is an important concern in the context of VOCs.
307 VOC B.1.1.7 was first detected in the United Kingdom and has been shown to exhibit
308 increased transmission with significantly increased reproduction number and attack rates
309 ^{33,34}. Transmission efficiency is a function of donor shedding, exposure time, sentinel
310 susceptibility, and potential environmental factors effecting stability during transmission.
311 One experimental study in preprint has found no difference in contact, fomite or short
312 distance airborne transmission between D614G and B.1.1.7 in the Syrian hamster,

313 however, numbers were low and no aerosol transmission was compared ³⁵. Our entry
314 data shows that there is increased entry of B.1.1.7 over lineage A for both human and
315 hamster ACE2, confirming the suitability of the Syrian hamster model for variant
316 comparison. Our data suggest that the increased transmission efficiency of B.1.1.7 may
317 not be a direct result of the shedding magnitude but that a lower dose of B.1.1.7 may be
318 sufficient for transmission. Under the applied experimental restrictions (200 cm, 1 hour)
319 both lineage A and B.1.1.7 transmitted equally as efficient. However, B.1.1.7 displayed
320 an increased airborne transmission competitiveness over lineage A in a dual infection
321 experiment. This has also previously been shown for D614G over the lineage A variant
322 ^{36,37} and for B.1.1.7 over D614G ³⁸, however, these studies did not look at airborne
323 transmission. Previously, the D614G competition and transmission experiments in
324 hamsters and ferrets suggested that the D614G mutation increased transmissibility ^{39,40}.
325 The additional N501Y mutation is specifically predicted to increase affinity for human
326 ACE2, partially explaining the dominance of B.1.1.7 and other new variants containing
327 both mutations ^{41,42}. Additional work is required to demonstrate conclusively if the
328 increased airborne competitiveness of B.1.1.7 in the hamster model is truly a result of
329 increased susceptibility due to better viral entry and/or decreased infectious dose. Our
330 data indicate that the Syrian hamster represents a valuable model to rapidly evaluate
331 transmission differences between novel VOCs

332 The increase in aerosol transmission potential of B.1.1.7 underscores the continuous
333 need for development and implementation of non-pharmaceutical preemptive
334 interventions. In the light of limited global vaccine coverage and the potential emergence
335 of escape mutants, ventilation, and air disinfection ^{43,44}, face masks and social distancing

336 ^{13,45}, should still be considered essential tools in COVID-19 exposure and transmission
337 risk mitigation strategies.

338

339 **Materials and Methods**

340 *Ethics Statement*

341 All animal experiments were conducted in an AAALAC International-accredited facility
342 and were approved by the Rocky Mountain Laboratories Institutional Care and Use
343 Committee following the guidelines put forth in the Guide for the Care and Use of
344 Laboratory Animals 8th edition, the Animal Welfare Act, United States Department of
345 Agriculture and the United States Public Health Service Policy on the Humane Care and
346 Use of Laboratory Animals. Work with infectious SARS-CoV-2 virus strains under BSL3
347 conditions was approved by the Institutional Biosafety Committee (IBC). For the removal
348 of specimens from high containment areas virus inactivation of all samples was performed
349 according to IBC-approved standard operating procedures.

350

351 *Cells and virus*

352 SARS-CoV-2 variant B.1.1.7 (hCoV320 19/England/204820464/2020, EPI_ISL_683466)
353 was obtained from Public Health England via BEI. SARS-CoV-2 strain nCoV-WA1-2020
354 (lineage A, MN985325.1) was provided by CDC, Atlanta, USA. Virus propagation was
355 performed in VeroE6 cells in DMEM supplemented with 2% fetal bovine serum, 1 mM L-
356 glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin (DMEM2). VeroE6 cells were
357 maintained in DMEM supplemented with 10% fetal bovine serum, 1 mM L- glutamine, 50

358 U/mL penicillin and 50 µg/ml streptomycin. At regular intervals mycoplasma testing was
359 performed. No mycoplasma and no contaminants were detected. For sequencing from
360 viral stocks, sequencing libraries were prepared using Stranded Total RNA Prep Ligation
361 with Ribo-Zero Plus kit per manufacturer's protocol (Illumina) and sequenced on an
362 Illumina MiSeq at 2 x 150 base pair reads. No nucleotide change was found >5% for
363 nCoV-WA1-2020, while for VOC B.1.1.7 **Supplementary Table 6** summarized the
364 mutations obtained.

365

366 *Plasmids*

367 The spike coding sequences for SARS-CoV-2 lineage A (nCoV-WA1-2020) and variant
368 B.1.1.7 (hCoV320 19/England/204820464/2020, EPI_ISL_683466) were truncated by
369 deleting 19 aa at the C-terminus. The S proteins with the 19 aa deletion of coronaviruses
370 were previously reported to show increased efficiency regarding incorporation into virions
371 of VSV^{46,47}. These sequences were codon optimized for human cells, then appended
372 with a 5' kozak expression sequence (GCCACC) and 3' tetra-glycine linker followed by
373 nucleotides encoding a FLAG-tag sequence (DYKDDDDK). These spike sequences were
374 synthesized and cloned into pcDNA3.1+(GenScript). Human and hamster ACE2
375 (Q9BYF1.2 and GQ262794.1, respectively), were synthesized and cloned into
376 pcDNA3.1+ (GenScript). All DNA constructs were verified by Sanger sequencing (ACGT).

377

378 *Receptor transfection*

379 BHK cells were seeded in black 96-well plates and transfected the next day with 100 ng
380 plasmid DNA encoding human or hamster ACE2, using polyethylenimine (Polysciences).
381 All downstream experiments were performed 24 h post-transfection.

382 *Pseudotype production and Luciferase-based cell entry assay*

383 Pseudotype production was carried as described previously⁴⁸. Briefly, plates pre-coated
384 with poly-L-lysine (Sigma–Aldrich) were seed with 293T cells and transfected the
385 following day with 1,200 ng of empty plasmid and 400 ng of plasmid encoding coronavirus
386 spike or no-spike plasmid control (green fluorescent protein (GFP)). After 24 h,
387 transfected cells were infected with VSVΔG seed particles pseudotyped with VSV-G, as
388 previously described^{48,49}. After one hour of incubating with intermittent shaking at 37 °C,
389 cells were washed four times and incubated in 2 mL DMEM supplemented with 2% FBS,
390 penicillin/streptomycin and L-glutamine for 48 h. Supernatants were collected,
391 centrifuged at 500xg for 5 min, aliquoted and stored at –80 °C. BHK cells previously
392 transfected with ACE2 plasmid of interest were inoculated with equivalent volumes of
393 pseudotype stocks. Plates were then centrifuged at 1200xg at 4 °C for one hour and
394 incubated overnight at 37 °C. Approximately 18–20 h post-infection, Bright-Glo luciferase
395 reagent (Promega) was added to each well, 1:1, and luciferase was measured. Relative
396 entry was calculated normalizing the relative light unit for spike pseudotypes to the plate
397 relative light unit average for the no-spike control. Each figure shows the data for two
398 technical replicates.

399

400 *Structural interaction analysis*

401 Structure modeling was performed using the human ACE2 and SARS-CoV-2 RBD crystal
402 structure, PDB ID 6M0J⁵⁰. Mutagenesis to model the residues that differ in the B.1.1.7
403 RBD and hamster ACE2 was performed in COOT⁵¹. The structure figure was generated
404 using the Pymol Molecular Graphics System (<https://www.schrodinger.com/pymol>).
405 Amino acid sequence alignments of human ACE2 (BAB40370.1) and hamster ACE2
406 (XP_005074266.1), and of SARS-CoV-2 RBD from the lineage A strain and B.1.1.7 variant,
407 were generated using Clustal Omega (<http://europaemc.org/article/MED/>).
408 Residues participating in the SARS-CoV-2 – ACE2 interface were noted as described by
409 Lan, et al⁵⁰.

410

411 *Duplex-qRT-PCR variant detection*

412 Duplex-qRT-PCR primers and probe were designed to distinguish between lineage A
413 SARS-CoV-2 and B.1.1.7 variant (**Supplemental Table 5**) in a duplex assay. The forward
414 and reverse primers were design to detect both variants while two probes were designed
415 to detect either variant. Five μ L RNA was tested with TaqMan™ Fast Virus One-Step
416 Master Mix (Applied Biosystems) using QuantStudio 3 Real-Time PCR System (Applied
417 Biosystems) according to instructions of the manufacturer. Relative fold-change
418 difference between both variants was calculated by applying the delta-delta Ct method,
419 ($2^{-\Delta\Delta C_t}$ method) with modifications.

420

421 *Inoculation experiments*

422 Four to six-week-old female and male Syrian hamsters (ENVIGO) were inoculated (10
423 animals per virus) intranasally (I.N) with either SARS-CoV-2 strain nCoV-WA1-2020

424 (lineage A) or hCoV320 19/England/204820464/2020 (B.1.1.7), or a 1:1 mixture of both
425 viruses. I.N. inoculation was performed with 40 μ L sterile DMEM containing 1×10^2 TCID₅₀
426 SARS-CoV-2. At five days post inoculation (DPI), five hamsters for each route were
427 euthanized, and tissues were collected. The remaining 5 animals for each route were
428 euthanized at 14 DPI for disease course assessment and shedding analysis. Hamsters
429 were weighted daily, and oropharyngeal swabs were taken on day 1, 2, 3 and 5. Swabs
430 were collected in 1 mL DMEM with 200 U/mL penicillin and 200 μ g/mL streptomycin.
431 Hamsters were observed daily for clinical signs of disease. Necropsies and tissue
432 sampling were performed according to IBC-approved protocols.

433

434 *Aerosol cages*

435 The aerosol transmission system consisted of two 7" X 11" X 9" plastic hamster boxes
436 (Lab Products, Inc.) connected with a 3" diameter tube (**Supplementary Figure 1**). The
437 boxes were modified to accept a 3" plastic sanitary fitting (McMaster-Carr) which enabled
438 the length between the boxes to be changed. The nominal tube lengths were 16.5, 106
439 and 200 cm. Airflow was generated with a vacuum pump (Vacuubrand) attached to the
440 box housing the naïve animals and was controlled with a float type meter/valve (King
441 Industries, McMaster-Carr). The airflow was adjusted for each tube length to be 30 cage
442 changes/hour and the flow was validated prior to starting the experiments by timing a
443 smoke plume through the tubes. The airflow of the original boxes is in through a filtered
444 top and out through an exhaust port in the side of the box. To ensure proper airflow from
445 the donor box to the naïve box, the top of the naïve box was sealed while the filter top of
446 the donor box remained open.

447 To ensure the system was able to contain aerosols the airtightness of the system was
448 validated with a negative pressure smoke test and a positive pressure leak test prior to
449 moving into a containment laboratory. To perform the negative pressure test the airflow
450 was adjusted to exhaust the system at 30 cage changes/hour, smoke was generated in
451 the donor cage with a WizardStick and escaped particulate was measured with a TSI
452 DustTrak DRX. To test the system under pressure the air flow was reversed, and the
453 joints were tested using a gas leak detector.

454

455 *Particle sizing*

456 Transmission cages were modified by introducing an inlet on the side wall of the infected
457 hamster side, and sample ports on each end of the connection tube for measurement of
458 particles in the air under constant airflow condition. Particles were generated by spraying
459 a 20% (v/v) glycerol solution with a standard spray bottle through the donor cage inlet.
460 The particle size was measured using a Model 3321 aerodynamic particle sizer
461 spectrometer (TSI). First, the donor cage was coated with three sprays at an interval of
462 30 seconds (s). The sample port was opened, and a sample was analyzed. Every 30 s a
463 new spray followed, and five samples were analyzed (5 runs, each 60 s) for both donor
464 side (primary infected side) and sentinel side.

465

466 *Aerosol Transmission experiments*

467 All transmission studies were conducted at a 2:2 ratio between donor and sentinels for
468 each transmission scenario tested and virus variant with 2 separate transmission cages
469 (N = 4 donors / 4 sentinels). To ensure no cross-contamination, the donor cages and the

470 sentinel cages were never opened at the same time, sentinel hamsters were not exposed
471 to the same handling equipment as donors and after each sentinel the equipment was
472 disinfected with either 70% ETOH or 5% Microchem.

473 Initially, transmission was studied assessing distance. Donor hamsters were infected
474 intranasally as described above with 8×10^4 TCID₅₀ SARS-CoV-2 (lineage A or B.1.1.7
475 variants). After 12 hours donor animals were placed into the donor cage and sentinels
476 were placed into the sentinel cage (2:2). Air flow was generated between the cages from
477 the donor to the sentinel cage at 30 changes/h. Hamsters were co-housed at 16.5 cm,
478 106 cm or 200 cm distance. Regular bedding was replaced by alpha-dri bedding to avoid
479 the generation of dust particles. Oropharyngeal swabs were taken for donors at 1 DPI
480 and for sentinels daily after exposure began. Swabs were collected in 1 mL DMEM with
481 200 U/mL penicillin and 200 µg/mL streptomycin. Exposure continued until respiratory
482 shedding was confirmed in sentinels on three consecutive days. Then donors were
483 euthanized, and sentinels were monitored until 14 DPE (days post exposure) for
484 seroconversion.

485 Second, transmission was studied assessing duration of exposure. Donor hamsters were
486 infected intranasally as described above with 8×10^4 TCID₅₀ SARS-CoV-2. After 24 hours
487 (1 DPI) or 72 hours (3 DPI) donor animals were placed into the donor cage and sentinels
488 were placed into the sentinel cage (2:2). Hamsters were co-housed at 200 cm distance
489 for 1 or 4 hours at an airflow rate of 30 changes/h. Oropharyngeal swabs were taken for
490 donors at day of exposure and for sentinels for three days after exposure.

491

492 *Variant competitiveness transmission chain*

493 Donor hamsters (N = 8) were infected intranasally as described above with 1×10^2 TCID₅₀
494 SARS-CoV-2 at a 1:1 ratio of lineage A and B.1.1.7 mixture. After 12 hours donor animals
495 were placed into the donor cage and sentinels (Sentinels 1, N = 8) were placed into the
496 sentinel cage (2:2) at 16.5 cm distance at an airflow of 30 changes/h. Hamsters were co-
497 housed for 24 h. The following day, donor animals were re-housed into regular rodent
498 caging and Sentinels 1 were placed into the donor cage of new transmission set-ups.
499 New sentinels (Sentinels 2, N = 8) were placed into the sentinel cage (2:2) at 16.5 cm
500 distance at an airflow of 30 changes/h. Hamsters were co-housed for 24 h. Then,
501 Sentinels 1 were re-housed into regular rodent caging and Sentinels 2 were placed into
502 the donor cage of new transmission set-ups. New sentinels (Sentinels 3, N = 8) were
503 placed into the sentinel cage (2:2) at 16.5 cm distance at an airflow of 30 changes/h.
504 Hamsters were co-housed for 24 h. Then, both Sentinels 2 and Sentinels 3 were re-
505 housed to regular rodent caging and monitored until 5 DPE. Oropharyngeal swabs were
506 taken for all animals at 2 DPI/DPE. All animals were euthanized at 5 DPI/DPE for
507 collection of lung tissue.

508

509 *Viral RNA detection*

510 Swabs from hamsters were collected as described above. Then, 140 μ L was utilized for
511 RNA extraction using the QIAamp Viral RNA Kit (Qiagen) using QIAcube HT automated
512 system (Qiagen) according to the manufacturer's instructions with an elution volume of
513 150 μ L. For tissues, RNA was isolated using the RNeasy Mini kit (Qiagen) according to
514 the manufacturer's instructions and eluted in 60 μ L. Sub-genomic (sg) viral RNA and
515 genomic (g) was detected by qRT-PCR^{52,53}. RNA was tested with TaqMan™ Fast Virus

516 One-Step Master Mix (Applied Biosystems) using QuantStudio 6 or 3 Flex Real-Time
517 PCR System (Applied Biosystems). SARS-CoV-2 standards with known copy numbers
518 were used to construct a standard curve and calculate copy numbers/mL or copy
519 numbers/g.

520

521 *Viral titration*

522 Viable virus in tissue samples was determined as previously described⁵⁴. In brief, lung
523 tissue samples were weighted, then homogenized in 1 mL of DMEM (2% FBS). VeroE6
524 cells were inoculated with ten-fold serial dilutions of homogenate, incubated 1 hours at
525 37°C and the first two dilutions washed twice with 2% DMEM. After 6 days cells were
526 scored for cytopathic effect. TCID₅₀/mL was calculated by the method of Spearman-
527 Karber.

528

529 *Serology*

530 Serum samples were analyzed as previously described⁵⁵. In brief, maxisorp plates
531 (Nunc) were coated with 50 ng spike protein (generated in-house) per well. Plates were
532 incubated overnight at 4°C. Plates were blocked with casein in phosphate buffered saline
533 (PBS) (ThermoFisher) for 1 hours at room temperature (RT). Serum was diluted 2-fold in
534 blocking buffer and samples (duplicate) were incubated for 1 hours at RT. Secondary
535 goat anti-hamster IgG Fc (horseradish peroxidase (HRP)-conjugated, Abcam) spike-
536 specific antibodies were used for detection and visualized with KPL TMB 2-component
537 peroxidase substrate kit (SeraCare, 5120-0047). The reaction was stopped with KPL stop
538 solution (Seracare) and plates were read at 450 nm. The threshold for positivity was

539 calculated as the average plus 3 x the standard deviation of negative control hamster
540 sera.

541

542 *Next-generation sequencing of virus*

543 For sequencing from swabs, total RNA was depleted of ribosomal RNA using the Ribo-
544 Zero Gold rRNA Removal kit (Illumina). Sequencing libraries were constructed using the
545 KAPA RNA HyperPrep kit following manufacturer's protocol (Roche Sequencing
546 Solutions). To enrich for SARS-CoV-2 sequence, libraries were hybridized to myBaits
547 Expert Virus biotinylated oligonucleotide baits following the manufacturer's manual,
548 version 4.01 (Arbor Biosciences, Ann Arbor, MI). Enriched libraries were sequenced on
549 the Illumina MiSeq instrument as paired-end 2 X 150 base pair reads. Raw fastq reads
550 were trimmed of Illumina adapter sequences using cutadapt version 1.1227 and then
551 trimmed and filtered for quality using the FASTX-Toolkit (Hannon Lab, CSHL). Remaining
552 reads were mapped to the SARS-CoV-2 2019-nCoV/USA-WA1/2020 (MN985325.1 using
553 Bowtie2 version 2.2.928 with parameters --local --no-mixed -X 1500. PCR duplicates
554 were removed using picard MarkDuplicates (Broad Institute) and variants were called
555 using GATK HaplotypeCaller version 4.1.2.029 with parameter -ploidy 2. Variants were
556 filtered for QUAL > 500 and DP > 20 using bcftools. We assessed the presence of N501Y,
557 D614G and P681H, and calculated the average to inform on the frequency of B.1.1.7
558 sequences in the sample.

559

560 Statistical Analysis

561 Significance test were performed as indicated where appropriate. Statistical significance
562 levels were determined as follows: ns = $p > 0.05$; * = $p \leq 0.05$; ** = $p \leq 0.01$; *** = $p \leq$
563 0.001; **** = $p \leq 0.0001$.

564

565 References

- 566 1 Goldman, E. Exaggerated risk of transmission of COVID-19 by fomites. *Lancet Infect Dis* **20**,
567 892-893, doi:10.1016/s1473-3099(20)30561-2 (2020).
- 568 2 Pitol, A. K. & Julian, T. R. Community Transmission of SARS-CoV-2 by Fomites: Risks and
569 Risk Reduction Strategies. *medRxiv*, 2020.2011.2020.20220749,
570 doi:10.1101/2020.11.20.20220749 (2020).
- 571 3 CDC. How COVID-19 Spreads. (2021).
- 572 4 Zhang, R., Li, Y., Zhang, A. L., Wang, Y. & Molina, M. J. Identifying airborne transmission as
573 the dominant route for the spread of COVID-19. *Proceedings of the National Academy of*
574 *Sciences* **117**, 14857-14863, doi:10.1073/pnas.2009637117 (2020).
- 575 5 Boone, S. A. & Gerba, C. P. Significance of Fomites in the Spread of Respiratory and Enteric
576 Viral Disease. *Applied and Environmental Microbiology* **73**, 1687-1696, doi:10.1128/aem.02051-
577 06 (2007).
- 578 6 Organization, W. H. Transmission of SARS-CoV-2: implications for infection prevention
579 precautions. (2020).
- 580 7 Herfst, S. *et al.* Airborne transmission of influenza A/H5N1 virus between ferrets. *Science (New*
581 *York, N.Y.)* **336**, 1534-1541, doi:10.1126/science.1213362 (2012).
- 582 8 Richard, M. *et al.* Influenza A viruses are transmitted via the air from the nasal respiratory
583 epithelium of ferrets. *Nature Communications* **11**, 766, doi:10.1038/s41467-020-14626-0 (2020).
- 584 9 Yen, H.-L. *et al.* Hemagglutinin–neuraminidase balance confers respiratory-droplet
585 transmissibility of the pandemic H1N1 influenza virus in ferrets. *Proceedings of the National*
586 *Academy of Sciences* **108**, 14264-14269, doi:10.1073/pnas.1111000108 (2011).
- 587 10 Zhou, J. *et al.* Defining the sizes of airborne particles that mediate influenza transmission in
588 ferrets. *Proc Natl Acad Sci U S A* **115**, E2386-e2392, doi:10.1073/pnas.1716771115 (2018).
- 589 11 Public Health England, V. T. G. SARS-CoV-2 variants of concern and variants under
590 investigation in England, . *Public Health England Technical briefing* **7** (2021).
- 591 12 WHO. COVID-19 Weekly Epidemiological Update, 25 February 2021. (2021).
- 592 13 Leung, N. H. L. *et al.* Respiratory virus shedding in exhaled breath and efficacy of face masks.
593 *Nature Medicine* **26**, 676-680, doi:10.1038/s41591-020-0843-2 (2020).
- 594 14 Port, J. R. *et al.* SARS-CoV-2 disease severity and transmission efficiency is increased for
595 airborne but not fomite exposure in Syrian hamsters. *bioRxiv*, 2020.2012.2028.424565,
596 doi:10.1101/2020.12.28.424565 (2020).
- 597 15 Sia, S. F. *et al.* Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature*,
598 doi:10.1038/s41586-020-2342-5 (2020).
- 599 16 Sia, S. F. *et al.* Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **583**,
600 834-838, doi:10.1038/s41586-020-2342-5 (2020).
- 601 17 Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in
602 England. *Science* **372**, eabg3055, doi:10.1126/science.abg3055 (2021).
- 603 18 Ramanathan, M., Ferguson, I. D., Miao, W. & Khavari, P. A. SARS-CoV-2 B.1.1.7 and B.1.351
604 spike variants bind human ACE2 with increased affinity. *The Lancet Infectious Diseases*,
605 doi:10.1016/S1473-3099(21)00262-0.

- 606 19 Laffeber, C., de Koning, K., Kanaar, R. & Lebbink, J. H. Experimental evidence for enhanced
607 receptor binding by rapidly spreading SARS-CoV-2 variants. *bioRxiv*, 2021.2002.2022.432357,
608 doi:10.1101/2021.02.22.432357 (2021).
- 609 20 Chan, J. F.-W. *et al.* Simulation of the Clinical and Pathological Manifestations of Coronavirus
610 Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease
611 Pathogenesis and Transmissibility. *Clinical Infectious Diseases*, doi:10.1093/cid/ciaa325 (2020).
- 612 21 Rosenke, K. *et al.* Defining the Syrian hamster as a highly susceptible preclinical model for
613 SARS-CoV-2 infection. *Emerg Microbes Infect*, 1-36, doi:10.1080/22221751.2020.1858177
614 (2020).
- 615 22 Yamagishi, T. Environmental sampling for severe acute respiratory syndrome coronavirus 2
616 (SARS-CoV-2) during a coronavirus disease (COVID-19) outbreak aboard a commercial cruise
617 ship. *medRxiv*, 2020.2005.2002.20088567, doi:10.1101/2020.05.02.20088567 (2020).
- 618 23 Lu, J. *et al.* COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou,
619 China, 2020. *Emerg Infect Dis* **26**, 1628-1631, doi:10.3201/eid2607.200764 (2020).
- 620 24 Fennelly, K. P. Particle sizes of infectious aerosols: implications for infection control. *Lancet*
621 *Respir Med* **8**, 914-924, doi:10.1016/s2213-2600(20)30323-4 (2020).
- 622 25 Brankston, G., Gitterman, L., Hirji, Z., Lemieux, C. & Gardam, M. Transmission of influenza A
623 in human beings. *Lancet Infect Dis* **7**, 257-265, doi:10.1016/s1473-3099(07)70029-4 (2007).
- 624 26 Bryche, B. *et al.* Massive transient damage of the olfactory epithelium associated with infection
625 of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. *Brain Behav Immun*,
626 doi:10.1016/j.bbi.2020.06.032 (2020).
- 627 27 Kutter, J. S. *et al.* SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets
628 over more than one meter distance. *Nature Communications* **12**, 1653, doi:10.1038/s41467-021-
629 21918-6 (2021).
- 630 28 Richard, M. *et al.* SARS-CoV-2 is transmitted via contact and via the air between ferrets. *Nat*
631 *Commun* **11**, 3496, doi:10.1038/s41467-020-17367-2 (2020).
- 632 29 Milton, D. K. A Rosetta Stone for Understanding Infectious Drops and Aerosols. *J Pediatric*
633 *Infect Dis Soc* **9**, 413-415, doi:10.1093/jpids/piaa079 (2020).
- 634 30 Hou, Y. J. *et al.* SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the
635 Respiratory Tract. *Cell* **182**, 429-446.e414, doi:10.1016/j.cell.2020.05.042 (2020).
- 636 31 Gralton, J., Tovey, E., McLaws, M.-L. & Rawlinson, W. D. The role of particle size in
637 aerosolised pathogen transmission: A review. *Journal of Infection* **62**, 1-13,
638 doi:<https://doi.org/10.1016/j.jinf.2010.11.010> (2011).
- 639 32 Yinda, C. K. *et al.* Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters
640 from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. *bioRxiv*,
641 2021.2005.2005.442780, doi:10.1101/2021.05.05.442780 (2021).
- 642 33 Volz, E. *et al.* Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*,
643 doi:10.1038/s41586-021-03470-x (2021).
- 644 34 Lindstrøm, J. C. *et al.* Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: Evidence
645 from contact tracing data in Oslo, January to February 2021. *medRxiv*,
646 2021.2003.2029.21254122, doi:10.1101/2021.03.29.21254122 (2021).
- 647 35 Mohandas, S. *et al.* Comparison of SARS-CoV-2 VOC 202012/01 (UK variant) and D614G
648 variant transmission by different routes in Syrian hamsters. *bioRxiv*, 2021.2003.2026.437153,
649 doi:10.1101/2021.03.26.437153 (2021).
- 650 36 Hou, Y. J. *et al.* SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
651 transmission in vivo. *Science*, doi:10.1126/science.abe8499 (2020).
- 652 37 Zhou, B. *et al.* SARS-CoV-2 spike D614G change enhances replication and transmission. *Nature*
653 **592**, 122-127, doi:10.1038/s41586-021-03361-1 (2021).
- 654 38 Ulrich, L. *et al.* Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in
655 animal models. *bioRxiv*, 2021.2006.2028.450190, doi:10.1101/2021.06.28.450190 (2021).

- 656 39 Plante, J. A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* **592**, 116-121,
657 doi:10.1038/s41586-020-2895-3 (2021).
- 658 40 Hou, Y. J. *et al.* SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
659 transmission in vivo. *Science* **370**, 1464-1468, doi:10.1126/science.abe8499 (2020).
- 660 41 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
661 *Cell* **181**, 281-292.e286, doi:10.1016/j.cell.2020.02.058 (2020).
- 662 42 Luring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2—What Do They Mean?
663 *JAMA* **325**, 529-531, doi:10.1001/jama.2020.27124 (2021).
- 664 43 Morawska, L. *et al.* How can airborne transmission of COVID-19 indoors be minimised? *Environ*
665 *Int* **142**, 105832, doi:10.1016/j.envint.2020.105832 (2020).
- 666 44 Nardell, E. A. & Nathavitharana, R. R. Airborne Spread of SARS-CoV-2 and a Potential Role for
667 Air Disinfection. *Jama* **324**, 141-142, doi:10.1001/jama.2020.7603 (2020).
- 668 45 Chu, D. K. *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person
669 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*
670 **395**, 1973-1987, doi:10.1016/s0140-6736(20)31142-9 (2020).
- 671 46 Fukushi, S. *et al.* Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome
672 coronavirus spike protein. *Journal of General Virology* **86**, 2269-2274,
673 doi:<https://doi.org/10.1099/vir.0.80955-0> (2005).
- 674 47 Kawase, M., Shirato, K., Matsuyama, S. & Taguchi, F. Protease-Mediated Entry via the
675 Endosome of Human Coronavirus 229E. *Journal of Virology* **83**, 712-721, doi:10.1128/jvi.01933-
676 08 (2009).
- 677 48 Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for
678 SARS-CoV-2 and other lineage B betacoronaviruses. *Nature Microbiology* **5**, 562-569,
679 doi:10.1038/s41564-020-0688-y (2020).
- 680 49 Takada, A. *et al.* A system for functional analysis of Ebola virus glycoprotein. *Proceedings of the*
681 *National Academy of Sciences* **94**, 14764-14769, doi:10.1073/pnas.94.26.14764 (1997).
- 682 50 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
683 receptor. *Nature* **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).
- 684 51 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta*
685 *Crystallogr D Biol Crystallogr* **66**, 486-501, doi:10.1107/s0907444910007493 (2010).
- 686 52 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
687 *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.3.2000045 (2020).
- 688 53 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
689 *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable*
690 *disease bulletin* **25**, 2000045, doi:10.2807/1560-7917.ES.2020.25.3.2000045 (2020).
- 691 54 van Doremalen, N. *et al.* Efficacy of antibody-based therapies against Middle East respiratory
692 syndrome coronavirus (MERS-CoV) in common marmosets. *Antiviral Res* **143**, 30-37,
693 doi:10.1016/j.antiviral.2017.03.025 (2017).
- 694 55 Yinda, C. K. *et al.* K18-hACE2 mice develop respiratory disease resembling severe COVID-19.
695 *bioRxiv*, doi:10.1101/2020.08.11.246314 (2020).

697

698

699

700

701

702

703 **Acknowledgements**

704 We would like to thank Emmie de Wit, Brandi Williamson, Natalie Thornburg, Sue Tong,
705 Sujatha Rashid, Ranjan Mukul, Kimberly Stemple, Craig Martens, Kent Barbian, Stacey
706 Ricklefs, Sarah Anzick, Rose Perry, Tom Jones, Ryan Stehlik, Seth Cooley and Shanda
707 Sarchette, and the animal care takers for their assistance during the study. The following
708 reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus
709 2, Isolate hCoV-19/England/204820464/2020, NR282 54000, contributed by Bassam
710 Hallis.

711

712 **Funding**

713 This work was supported by the Intramural Research Program of the National Institute of
714 Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
715 (1ZIAAI001179-01).

716

717 **Author contributions**

718 JRP, KCY, VJM designed the studies.

719 JRP, KCY, BJF, VA, MH, JES, NvD performed the experiments.

720 JRP, KCY, CS analyzed results.

721 JRP, KCY, VJM wrote the manuscript.

722 All co-authors reviewed the manuscript.


723

724 **Materials and Correspondence**

725 All material requests should be sent to Vincent J. Munster, vincent.munster@nih.gov.


726

727 **Figures and Figure Legends:**
728



729

730 **Figure 1: Design and validation of aerosol transmission cages.** Transmission cages
731 were designed to model airborne transmission between Syrian hamsters at 16.5 cm, 106
732 cm and 200 cm distance. Droplets were generated by spraying a 20% glycerol/water
733 solution into the donor cage. Size of particles travelling between donor and sentinel cages
734 were determined. **A/B/C.** Particle reduction by aerodynamic diameter between the donor
735 and sentinel cage at 16.5 cm (A) 106 cm (B) and 200 cm distance (C). Dotted line = 95%
736 reduction in particles. Aerodynamic diameter 1-10 μm. **D/E/F.** Schematic visualization of
737 the transmission cages at 16.5 cm (A), 106 cm (B) and 200 cm distance (C) and
738 corresponding particle distribution detected in each donor and sentinel cage.



739

740 **Figure 2: SARS-CoV-2 lineage A variant transmits efficiently over 200 cm distance.**

741 Donor Syrian hamsters were inoculated with 8×10^4 TCID₅₀ SARS-CoV-2. After 12 hours,

742 donors were introduced to the upstream cage and sentinels (2:2 ratio) into the


743 downstream cage. Exposure was continued for three days. To demonstrate transmission,

744 sentinels were monitored for start and continuation of respiratory shedding. Viral load in

745 oropharyngeal swabs of sentinels was measured by gRNA and sgRNA collected at 12,

746 24 and 48 hours post exposure to the donors. **A/B.** Exposure at 16.5 cm distance. **C/D.**


747 Exposure at 106 cm distance. **E/F**. Exposure at 200 cm distance. Truncated violin plots
 748 depicting median, quantiles and individual, N = 4, two-way ANOVA, followed by Sidak's
 749 multiple comparisons test. Abbreviations: g, gnomic; sg, subgenomic.
 750



751
 752 **Figure 3: B.1.1.7 infection in Syrian hamsters is comparable to lineage A variant**
 753 **infection.** We compared lineage A variant and B.1.1.7 receptor binding to hamster and

754 human ACE2 *in silico* and *in vitro*. For *in vivo* comparison, Syrian hamsters were
755 inoculated with 10^2 TCID₅₀ via the intranasal route. **A.** Differences between hamster and
756 human ACE2 and between lineage A and B.1.1.7 SARS-CoV-2 RBD are shown on the
757 structure of the human ACE2-RBD complex (PDB 6M0J, ⁵⁰). The structure is shown with
758 cartoon representation with human ACE2 colored black and RBD colored gray.
759 Sidechains of the differing residues and surrounding residues involved in the interface,
760 as defined by Lan *et al.* ⁵⁰ are shown as sticks. The boxes show close up views
761 highlighting residues that differ between the two RBDs and between human and hamster
762 ACE2 within the interface, which were modelled using COOT ⁵¹. The side chains of
763 residues at the N501Y substitution in the B.1.1.7 variant RBD, as well as the hamster
764 ACE2 H34Q and M82N substitutions are colored red and shown superposed to the
765 sidechain of the original residue. **B.** Amino acid sequence alignments of human ACE2
766 (BAB40370.1) and hamster ACE2 (XP_005074266.1), and of SARS-CoV-2 RBD from the
767 A lineage strain and B.1.1.7 (bottom) generated using Clustal Omega. Residues involved
768 in the RBD-ACE2 interaction, as defined by Lan, et al, ⁵⁰, are noted in orange. Residues
769 that participate in intermolecular hydrogen bonding or salt bridges are marked with a black
770 dot. ACE2 residues that differ between hamster and human within the interface are
771 outlined with a box and highlighted in (A). RBD residue 501, which differs between the A
772 lineage variant and B.1.1.7 isolate, is also highlighted with a red box. **C.** BHK cells
773 expressing either human ACE2 or hamster ACE2 were infected with pseudotyped VSV
774 reporter particles with the spike proteins of WA1 and B.1.1.7 and B.1.351, luciferase was
775 measured and normalized to no spike controls as a readout for cell entry Relative entry
776 to no spike control for human and hamster ACE2 is depicted. Truncated violin plots

777 depicting median, quantiles and individual, N = 14, Mann-Whitney test). **D.** Relative
778 weight loss in hamsters after lineage A or B.1.1.7 variant inoculation. Graph shows
779 median and 95% CI, N = 10. **E.** Viral load as measured by gRNA and sgRNA in lungs
780 collected at day 5 post inoculation. Truncated violin plots depicting median, quantiles and
781 individual, N = 5, ordinary two-way ANOVA followed by Sidak's multiple comparisons test.
782 **F.** Infectious virus determined by titration in lungs collected at day 5 post inoculation.
783 Truncated violin plots depicting median, quantiles and individual, N = 5. **G.** Binding
784 antibodies against spike protein of SARS-CoV-2 in serum obtained 14 days post
785 inoculation. Truncated violin plots depicting median, quantiles and individual, N = 5,
786 Mann-Whitney test. ELISA was performed once. **H.** Viral load as measured by sgRNA in
787 oropharyngeal swabs collected at 0, 12, 24, 36, 48, 72 and 120 hours post inoculation.
788 Truncated violin plots depicting median, quantiles and individual, N = 10. **I.** Area under
789 the curve (AUC) analysis of cumulative respiratory shedding as measured by viral load in
790 swabs. Truncated violin plots depicting median, quantiles and individual, N = 5, Mann-
791 Whitney test, blue = lineage A, red = B.1.1.7, N. P-values are indicated where appropriate.
792 Abbreviations: A, lineage A variant; g, genomic; sg, subgenomic; RBD, receptor binding
793 domain; ACE2, Angiotensin-converting enzyme 2.




795 **Figure 4: B.1.1.7 aerosol transmission efficiency is increased**

796 Comparison of aerosol transmission efficiency of lineage A and B.1.1.7 SARS-CoV-2
797 variants in the Syrian hamster. **A/B.** Donor Syrian hamsters were inoculated with 8×10^4
798 TCID₅₀ SARS-CoV-2 B.1.1.7 variant. After 12 hours, donors were introduced to the
799 upstream cage and sentinels (2:2 ratio) into the downstream cage. Exposure was
800 continued for three days. To demonstrate transmission, sentinels were monitored for start
801 and continuation of respiratory shedding. Viral load in oropharyngeal swabs of sentinels
802 was measured by gRNA and sgRNA collected at 12, 24 and 48 hours post exposure to
803 the donors. Exposure at 106 cm distance. **C/D.** Exposure at 200 cm distance. **E/F.** Donor
804 Syrian hamsters were inoculated with 8×10^4 TCID₅₀ SARS-CoV-2 B.1.1.7 variant or
805 lineage A (N = 4, respectively). After 12 hours, donors were introduced to the upstream
806 cage and sentinels (2:2 ratio) into the downstream cage. Exposure was limited to four
807 hours. gRNA and sgRNA in oropharyngeal swabs were collected at 24, 48 and 72 hours
808 post exposure to the donors. **G/H.** Exposure was limited to one hour for B.1.1.7 and
809 lineage A (N = 4, respectively). gRNA and sgRNA in oropharyngeal swabs were collected
810 at 24, 48 and 72 hours post exposure to the donors. **I/J.** Viral load in oropharyngeal swabs
811 of donors was measured by gRNA and sgRNA collected 24 hours post inoculation.
812 Truncated violin plots depicting median, quantiles and individual, blue = lineage A, red =
813 B.1.1.7, N = 4 for each variant, two-way ANOVA, followed by Sidak's multiple
814 comparisons test. P-values are indicated where appropriate. Abbreviations: A, lineage A
815 variant; g, genomic; sg, subgenomic.

816

817




823 transmission chain design. Animals were exposed at a 2:2 ratio, exposure occurred on
824 consecutive days and lasted for 24 hours for each chain link. **B/C.** Respiratory shedding
825 measured by viral load in oropharyngeal swabs; measured by gRNA and sgRNA on day
826 2 post exposure. Truncated violin plots depicting median, quantiles and individuals, N =
827 8. **D.** Corresponding infectious virus in oropharyngeal swabs, measured by titration.
828 Truncated violin plots depicting median, quantiles and individuals, N = 8. **E.**
829 Corresponding infectious virus in lungs sampled five days post exposure, measured by
830 titration. Truncated violin plots depicting median, quantiles and individuals, N = 8. **F.**
831 Gross pathology of lungs at day 5 post exposure. **G.** Percentage of B.1.1.7 detected in
832 oropharyngeal swabs taken at day 2 post exposure for each individual donor and sentinel,
833 determined by deep sequencing. Pie-charts depict individual animals. Red = B.1.1.7, blue
834 = lineage A, grey = no viral RNA present in sample, and transparent color = duplex-qRT-
835 PCR confirmed viral RNA presence in sample but sequencing unsuccessful due to low
836 RNA quality.
837

838

Supplementary Material

839




840

841 **Supplemental Figure 1: Aerosol transmission cages. A/B.** Design of a new caging
842 system in which two hamster cages could be separated at 3 different distances. The
843 distances chosen were nominally 16.5 cm, 106 cm and 200 cm. The distance could be
844 adapted by swapping out a 76 mm inside diameter connection tube. Cages were installed
845 on autoclavable stainless steel shelves (Metro) inside a BSL-4 containment laboratory.
846 Airflow was measured by flowmeters mounted to the shelves. Air was pulled through the
847 system by a negative-pressure pump (Vacuubrand) and filtered through a hepa-filter
848 before the exhaust.

849

850



851

852 **Supplementary Figure 2: B.1.1.7 and lineage A aerosol transmission efficiency at**

853 **three days post inoculation.** Comparison of aerosol transmission efficiency of lineage

854 A and B.1.1.7 SARS-CoV-2 variants in the Syrian hamster. Donor Syrian hamsters were

855 inoculated with 8×10^4 TCID₅₀ SARS-CoV-2 lineage A or B.1.1.7 variant. After 72 hours,

856 donors were introduced to the upstream cage and sentinels (2:2 ratio) into the

857 downstream cage. Exposure was limited to one hour for B.1.1.7 and lineage A (N = 4,

858 respectively). **A.** Viral load in oropharyngeal swabs of donors collected 72 hours post

859 inoculation was measured by gRNA and sgRNA. **B/C.** To demonstrate transmission,


860 sentinels were monitored for start and continuation of respiratory shedding. Viral load in

861 oropharyngeal swabs of sentinels was measured by gRNA and sgRNA; swabs were

862 collected at 24, 48 and 72 hours post exposure to the donors. Exposure at 200 cm
863 distance. Truncated violin plots depicting median, quantiles and individuals, blue =
864 lineage A, red = B.1.1.7. Abbreviations: A, lineage A variant; g, genomic; sg, subgenomic.

865

866



867

868 **Supplementary Figure 3: Dual infection with lineage A and B.1.1.7 variant in the**

869 **Syrian hamster.** Animals (N = 10) were inoculated with both lineage A and B.1.1.7

870 variant with 10^2 TCID₅₀ via the intranasal route (1:1 ratio), **A.** Relative weight loss in

871 hamsters after dual inoculation in comparison to lineage A or B.1.1.7 variant inoculation.

872 Graph shows median and 95% CI, N = 10. **B.** Respiratory shedding as measured by

873 sgRNA in oropharyngeal swabs collected at 0, 12, 24, 36, 48, 72 and 120 hours post

874 inoculation. Truncated violin plots depicting median, quantiles and individual, N = 10. **C.**

875 Donor animals (N = 8) were inoculated with both lineage A and B.1.1.7 variant with 10^2

876 TCID₅₀ via the intranasal route (1:1 ratio), and three groups of sentinels (Sentinels 1, 2

877 and 3) were exposed subsequently at 16.5 cm distance. Ratio of B.1.1.7 and lineage A

878 variant found in oropharyngeal swabs taken at day 2 post exposure/inoculation for each

879 individual donor and sentinel, measured by duplex-qRT-PCR and depicted by ct

880 foldchange (B.1.1.7 over lineage A variant). Colors refer to scale on the right. Samples

881 for which only one variant was detected by PCR were set to 25,000. Abbreviations: A,
882 lineage A variant; sg, subgenomic.
883

884 **Supplementary Table 1: Aerosol Transmission Cage Validation Parameters.**

885 Special transmission cages were designed to model airborne transmission between
886 Syrian hamsters. Volume of air (cages plus connection tube), air flow velocity in the
887 tube and time for particles to traverse is provided at a cage air change rate of 30/h.

888

Cage system	Volume (L)	Linear velocity (cm/min)	Time (sec)
Connecting tube (200 cm)	1073	420	26.7692784
Connecting tube (106 cm)	945	370	15.059599
Connecting tube (16.5 cm)	837	327	2.80215197

889

890

891 **Supplementary Table 2: anti-spike ELISA results for sentinels in aerosol**
892 **transmission studies.** Presence of SARS-CoV-2 spike IgG antibodies in sentinels co-
893 housed at 16.5, 106 and 200 cm distance from lineage A or B.1.1.7(*) variant inoculated
894 donor hamsters. Detected in serum obtained 14 days post exposure. negative (neg):
895 optical density (at 450 nm) < 0.124, positive (pos) optical density (at 450 nm) ≥ 0.124.

Condition	Animal	Seroconverted
16.5 cm	S1	pos
	S2	pos
	S3	pos
	S4	pos
106 cm	S1	pos*
	S2	pos*
	S3	pos*
	S4	pos*
	S5	pos
	S6	pos
	S7	pos
	S8	pos
200 cm	S1	pos*
	S2	pos*
	S3	pos*
	S4	pos*
	S5	pos
	S6	pos
	S7	pos
	S8	pos

896

897

898

899 **Supplementary Table 3: Pathological assessment of lungs collected at 5 days post**
 900 **exposure.** Donor animals (N = 8) were inoculated with both lineage A and B.1.1.7 variant
 901 with 10² TCID₅₀ via the intranasal route (1:1 ratio), and three groups of sentinels
 902 (Sentinels 1, 2 and 3) were exposed subsequently at 16.5 cm distance. At five days post
 903 exposure, lungs were observed for gross pathology.

Identification	COVID-19 phenotype	Gross pathological assessment
Sentinel 1.1	N/A	bilateral focally extensive dorsal poorly circumscribed dark red discoloration
Sentinel 1.2	N/A	multifocal poorly circumscribed dark red discoloration
Sentinel 1.3	Yes	multifocal to coalescing foci of well circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 1.4	Yes	multifocal foci of well circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 1.5	N/A	focus of discoloration on the ventral margin on the left lobe, but no clear foci
Sentinel 1.6	Yes	multifocal foci of well circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 1.7	Yes	multifocal to coalescing foci of well circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 1.8	Yes	multifocal foci of well circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 2.1	N/A	multifocal foci of poorly circumscribed dark red discoloration suggestive of interstitial pneumonia
Sentinel 2.2	N/A	focally extensive foci of poorly circumscribed dark red discoloration
Sentinel 2.3	No	normal
Sentinel 2.4	No	normal
Sentinel 2.5	No	normal
Sentinel 2.6	No	normal
Sentinel 2.7	N/A	focally extensive foci of poorly circumscribed dark red discoloration
Sentinel 2.8	N/A	focally extensive foci of poorly circumscribed dark red discoloration
Sentinel 3.1	No	normal
Sentinel 3.2	No	normal
Sentinel 3.3	No	normal
Sentinel 3.4	No	normal
Sentinel 3.5	No	normal
Sentinel 3.6	No	normal
Sentinel 3.7	No	normal
Sentinel 3.8	No	normal

904

905 **Supplementary Table 4: qRT-PCR and sequencing results for donor and sentinel**
 906 **animals.** Donor animals (N = 8) were inoculated with both lineage A and B.1.1.7 variant
 907 with 10² TCID₅₀ via the intranasal route (1:1 ratio), and three groups of sentinels
 908 (Sentinels 1, 2 and 3) were exposed subsequently at 16.5 cm distance. Viral load in
 909 copies/reaction (measured by qRT-PCR) and percentage of B.1.1.7 detected in
 910 oropharyngeal swabs taken at day 2 post exposure for each individual donor and sentinel,
 911 determined by deep sequencing (expressed as %) and expressed as fold-change over
 912 lineage A as measured by duplex-qRT-PCR.

Animal	raw reads	qc reads	Viral RNA copies/reaction	% B.1.1.7	PCR fold-change
Donor 1	9697	9289	1239	54	0.87408891
Donor 2	77807	75255	85054	45	0.67126948
Donor 3	78379	75218	103141	67.66667	1.69959284
Donor 4	87992	85444	101401	70	2.1594464
Donor 5	85062	82728	199462	74.66667	2.93509401
Donor 6	135883	132657	254909	62	1.48700317
Donor 7	45156	43638	71343	57.66667	1.2711726
Donor 8	93687	91017	93356	57.66667	1.30263123
Sentinel 1.1	65408	63416	126315	99	4161.61905
Sentinel 1.2	41250	39943	38272	47	1.18602528
Sentinel 1.3	112221	107500	20842	98.33333	395.151923
Sentinel 1.4	107062	101891	62637	96	110.145084
Sentinel 1.5	91154	88209	42500	96.66667	803.405938
Sentinel 1.6	136060	131881	16994	58	1.12334412
Sentinel 1.7	44594	43114	115352	98	2303.5488
Sentinel 1.8	99311	96261	169096	16	0.12975316
Sentinel 2.1	131545	126930	29513	failed	0.00073727
Sentinel 2.3	33284	31942	4003	100	18001.5885
Sentinel 2.4	25906	25000	4056	100	20922.7397
Sentinel 2.6	10848	10219	522	failed	* only B.1.1.7 detected
Sentinel 3.2	154787	141295	65	failed	* only B.1.1.7 detected

913

914 **Supplementary Table 5: Duplex-qRT-PCR Primers and Probes**

Primer/probe	Sequence (5' → 3')
VM3256-RML-(drop out)	VIC-TGTTACTTGGTTCCATGCTATACATG-ZEN-IBHQ
VM3256-RML-(detection)	FAM-GTTCCATGCTATCTCTGGGACC--ZEN-IBHQ
VM3254-RML-F	AAAGTTTTTCAGATCCTCAG
VM3255-RML-R	GTTAGACTTCTCAGTGGAAG

915

916

917 **Supplementary Table 6: Sequence results of virus stock B.1.1.7**

ORF	a.a. change	Percentage
nsp6	D165G	14
nsp6	L257F	18
nsp7	V11I	13

918